Author

L. Meyaard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 8 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 6 Assay:proteomics· 4 Research Focus:differential expression· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:development & morphogenesis· 2

Frequent Co-Authors

H. J. Von Richthofen· 4 shared M. I. Pascoal Ramos· 3 shared M. van der Vlist· 3 shared A. Singh· 2 shared C. Kesmir· 2 shared E. Elshof· 2 shared G. H. A. Westerlaken· 2 shared L. J. Bont· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

H. J. Von Richthofen

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

A novel bioinformatics pipeline for the identification of immune inhibitory receptors as potential therapeutic targets

A. Singh, A. Miranda Bedate, H. J. Von Richthofen, S. V. Vijver, M. van der Vlist, R. Kuhn, A. Yermanos, J. J. Kuball, C. Kesmir, M. I. Pascoal Ramos, L. Meyaard

The paper introduces a bioinformatics pipeline to identify known and putative immune inhibitory receptors as therapeutic targets using machine learning and transcriptomics data.

bioRxiv · Oct 24, 2023Immunology

Macrophages sense ECM mechanics and growth factor availability through cytoskeletal remodeling to regulate their tissue repair program

M. L. Meizlish, Y. Kimura, S. D. Pope, R. Matta, C. Kim, N. Philip, L. Meyaard, A. Gonzalez, R. Medzhitov

bioRxiv · Jun 28, 2023 · PreprintImmunology

VSTM1-v2 does not drive human Th17 cell differentiation

H. J. von Richthofen, F. M. J. Hafkamp, A. van Haperen, E. C. de Jong, L. Meyaard

This study shows VSTM1-v2 does not enhance DC-driven or cytokine-driven Th17 cell differentiation in human naive CD4+ T cells.

bioRxiv · Jun 28, 2022 · PreprintImmunology

Soluble signal inhibitory receptor on leukocytes-1 is released from activated neutrophils by proteinase 3 cleavage

H. J. von Richthofen, G. H. A. Westerlaken, D. Gollnast, S. Besteman, E. M. Delemarre, K. Rodenburg, P. Moerer, D. A. C. Stapels, A. K. Andiappan, O. Rotzschke, S. Nierkens, H. L. Leavis, L. J. Bont, S. H. M. Rooijakkers, L. Meyaard

The paper shows that activated neutrophils release soluble SIRL-1 via proteinase 3 cleavage, and that sSIRL-1 is present in vivo in RSV and COVID-19 patients.

bioRxiv · Mar 3, 2022Immunology

Impaired LAIR-1-mediated immune control due to collagen degradation in fibrosis

T. Carvalheiro, W. Marut, M. I. Pascoal Ramos, S. Garcia, D. Fleury, A. J. Affandi, A. S. Meijers, B. Giovannone, R. G. Tieland, E. Elshof, A. Ottria, M. Cossu, M. L. Meizlish, T. Veenendaal, M. Ramanujam, , L. Meyaard

The paper investigates how impaired LAIR-1-collagen interaction in fibrosis contributes to inflammation and fibrosis, finding that dysfunctional collagen ligands and matrix metalloproteinases drive disease progression.

bioRxiv · Dec 7, 2021Immunology

Signal Inhibitory Receptor on Leukocytes-1 recognizes S100 proteins

M. Rumpret, H. J. von Richthofen, M. van der Linden, G. H. A. Westerlaken, C. Talavera Ormeno, T. Y. Low, H. Ovaa, L. Meyaard

This study identifies S100 proteins as ligands for the inhibitory receptor SIRL-1, showing that SIRL-1 suppresses neutrophil ROS production via binding to S100A6.

bioRxiv · May 14, 2021Immunology

Identification of a novel conserved signaling motif in CD200 Receptor required for its inhibitory function

L. M. Timmerman, J. F. de Graaf, N. Satravelas, C. Kesmir, L. Meyaard, M. van der Vlist

The paper identifies a unique conserved signaling motif in CD200R that mediates its inhibitory function, distinct from the common NPxY motif.

bioRxiv · Dec 17, 2020Immunology

Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction

M. I. P. Ramos, L. Tian, E. J. de Ruiter, C. Song, A. Paucarmayta, A. Singh, E. Elshof, S. V. Vijver, J. Shaik, J. Bosiacki, Z. Cusumano, L. Liu, S. Langermann, S. Willems, D. Flies, L. Meyaard

The paper demonstrates that NC410, a LAIR-2 Fc protein, blocks LAIR-1-collagen interaction, enhancing T cell activity and reducing tumor growth in humanized models.

bioRxiv · Oct 21, 2020Cancer Biology

Inhibitory CD200-receptor signaling is rewired by type I interferon

M. van der Vlist, M. I. Pascoal Ramos, L. L. van den Hoogen, S. Hiddingh, L. Timmerman, T. A. P. de Hond, E. D. Kaan, M. van der Kroef, R. J. Lebbink, F. M. A. Peters, W. Khoury-Hanold, R. Fritsch-Stork, T. Radstake, L. Meyaard

This study shows that type I interferon alters CD200R signaling by promoting RasGAP cleavage, converting CD200R from an inhibitor to a potentiator of IFNG mRNA production in SLE patients.

bioRxiv · Feb 6, 2020Immunology

Long-term expanding human airway organoids for disease modelling.

N. Sachs, D. D. Zomer-van Ommen, A. Papaspyropoulos, I. Heo, L. Bottinger, D. Klay, F. Weeber, G. Huelsz-Prince, N. Iakobachvili, M. C. Viveen, A. Lyubimova, L. Teeven, S. Derakhshan, J. Korving, H. Begthel, , H. Clevers

This study establishes long-term-expanding human airway organoids from broncho-alveolar biopsies or lavage material, enabling disease modeling of cystic fibrosis, lung cancer, and RSV infection.

bioRxiv · May 9, 2018Cell Biology